Severe hepatic injury and adulterated Chinese medicines [8]

British Medical Journal

Volumn 332, Issue 7536, 2006, Pages 304-305

  Lai, Vincent ^a   Smith, Amanda ^a   Thorburn, Douglas ^a   Raman, V S ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b GEORGE ELIOT HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FENFLURAMINE; HERBACEOUS AGENT; N NITROSOFENFLURAMINE; UNCLASSIFIED DRUG;

CHINESE MEDICINE; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; HEPATITIS; HUMAN; INCIDENCE; LETTER; LIVER GRAFT; LIVER INJURY; LIVER TOXICITY; OBESITY; PRIORITY JOURNAL; UNITED KINGDOM;

APPETITE DEPRESSANTS; DRUGS, CHINESE HERBAL; HUMANS; LIVER DISEASES;

EID: 32544458359     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.332.7536.304-b     Document Type: Letter

References (4)

1. Medicines and Healthcare products Regulatory Agency. Directive 2004/24/EC: Full regulatory impact assessment: directive on traditional herbal medicinal products. www.mhra.gov.uk/home/groups/pl-p/documents/ publication/con2022468.pdf (accessed 19 Jan 2006).
2. Connoly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8.
3. Hasegawa R, Futakuchi M, Mizoguchi Y, Yamaguchi T, Shirai T, Ito N, et al. Studies of initiation and promotion of carcinogenesis by N-nitroso compounds. Cancer Lett 1998;123:185-91.
4. The European Parliament and the Council of the European Union. Directive 2004/24/EC of the European Parliament and of the Council. Official Journal of the European Communities 2004;L136:85-90.